NCT02449551View on ClinicalTrials.gov

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 10, 2016

Primary Completion Date

December 30, 2020

Study Completion Date

August 27, 2021

Conditions
Advanced Gastric Adenocarcinoma
Interventions
DRUG

Volitinib

Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.

Trial Locations (1)

135-710

Samsung Medical center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02449551 - Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment | Biotech Hunter | Biotech Hunter